As Korea Pharmas Look To U.S., U.S. VC Looks To Korea
This article was originally published in PharmAsia News
Executive Summary
NEW YORK - Oxford Bioscience Partners has chosen Korea as its first Asian country to invest in via a partnership with Hanwha Venture Capital in Seoul
You may also be interested in...
Oxford BioSciences Jonathan Fleming And Chris Kim On Investing in Korea: An Interview With PharmAsia News (Part 2 of 2)
All eyes are on the Korea-Seoul Life Science Fund to see how the collaboration between the Boston-based venture capital firm Oxford Biosciences, Korea’s Hanwha Venture Capital, the Seoul Metropolitan Government and the Korea Institute for Advancement of Technology under the Ministry of Knowledge Economy will evolve.
Oxford BioSciences Jonathan Fleming And Chris Kim On Investing in Korea: An Interview With PharmAsia News (Part 1 of 2)
All eyes are on the Korea-Seoul Life Science Fund to see how the collaboration between the Boston-based venture capital firm Oxford Biosciences, Korea’s Hanwha Venture Capital, the Seoul Metropolitan Government and the Korea Institute for Advancement of Technology under the Ministry of Knowledge Economy will evolve.
Seoul Seeks To Expand Biomedical Fund With MOUs Signed With U.S. States Massachusetts And Maryland
SEOUL - The Seoul Metropolitan Government is pushing to expand its KRW 100 billion ($92.2 million) biomedical fund, established last year by the Boston venture capital firm Oxford Bioscience Partners and Korea's Hanwha Venture Capital to boost Korea's life sciences industries